Auger electron emitter against multiple myeloma - targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4'-thio-2'-deoxyuridine

Nuclear Medicine and Biology

Volumn 38, Issue 7, 2011, Pages 1067-1077

  Morgenroth, Agnieszka ^a,b   Dinger, Cornelia ^a   Zlatopolskiy, Boris D ^a   Al Momani, Ehab ^a   Glatting, Gerhard ^a   Mottaghy, Felix M ^b   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

125I ITdU; Auger electron emitter; Multiple myeloma; Thymidine analogue

Indexed keywords

5 IODO 4' THIO 2' DEOXYURIDINE I 125; ANTINEOPLASTIC AGENT; CASPASE 3; DEXAMETHASONE; DNA; FLOXURIDINE; INTERLEUKIN 6; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL MATURATION; CELL TRANSPORT; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG SENSITIVITY; ELECTRON THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE MYELOMA; PHENOTYPE; PROTEIN CLEAVAGE; WESTERN BLOTTING;

APOPTOSIS; BIOLOGICAL TRANSPORT; CASPASE 3; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYURIDINE; DNA; DNA FRAGMENTATION; DRUG RESISTANCE, NEOPLASM; ELECTRONS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM STAGING; THYMIDINE;

EID: 80053581808     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.02.018     Document Type: Article

References (40)

1. Alexanian R., Barlogie B., Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986, 105:8-11.
2. Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021-1030.
3. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
4. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
5. Barlogie B., Shaughnessy J., Tricot G., Jacobson J., Zangari M., Anaissie E., et al. Treatment of multiple myeloma. Blood 2004, 103:20-32.
6. Drewinko B., Alexanian R., Boyer H., Barlogie B., Rubinow S.I. The growth fraction of human myeloma cells. Blood 1981, 57:333-338.
7. Scudla V., Ordeltova M., Bacovsky J., Vytrasova M., Sumna E., Martinek A., et al. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma. Neoplasma 2003, 50:363-371.
8. Hideshima T., Chauhan D., Podar K., Schlossman R.L., Richardson P., Anderson K.C. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001, 28:607-612.
9. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2:175-187.
10. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002, 21:5673-5683.
11. Uchiyama H., Barut B.A., Mohrbacher A.F., Chauhan D., Anderson K.C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993, 82:3712-3720.
12. Blasberg R.G., Roelcke U., Weinreich R., Beattie B., von Ammon K., Yonekawa Y., et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 2000, 60:624-635.
13. Eary J.F., Mankoff D.A., Spence A.M., Berger M.S., Olshen A., Link J.M., et al. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999, 59:615-621.
14. Ryser J.E., Bläuenstein P., Rémy N., Weinreich R., Hasler P.H., Novak-Hofer I., et al. [76Br]bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. Nucl Med Biol 1999, 26:673-679.
15. Shields A.F. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 2003, 44:1432-1434.
16. Baranowska-Kortylewicz J., Makrigiorgos G.M., Van den Abbeele A.D., Berman R.M., Adelstein S.J., Kassis A.I. 5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 1991, 21:1541-1551.
17. Buchegger F., Adamer F., Schaffland A.O., Kosinski M., Grannavel C., Dupertuis Y.M., et al. Highly efficient DNA incorporation of intratumourally injected [125I]iododeoxyuridine under thymidine synthesis blocking in human glioblastoma xenografts. Int J Cancer 2004, 110:145-149.
18. Dupertuis Y.M., Vazquez M., Mach J.P., De Tribolet N., Pichard C., Slosman D.O., et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res 2001, 61:7971-7977.
19. Toyohara J., Hayashi A., Sato M., Tanaka H., Haraguchi K., Yoshimura Y., et al. Rationale of 5-125I-iodo-4'-thio-2'-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med 2002, 43:1218-1226.
20. Morgenroth A., Deisenhofer S., Glatting G., Kunkel F.H., Dinger C., Zlatopolskiy B., et al. Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4'-thio-2'-deoxyuridine. Clin Cancer Res 2008, 14:7311-7319.
21. Reske S.N., Deisenhofer S., Glatting G., Zlatopolskiy B.D., Morgenroth A., Vogg A.T., et al. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, beta-, or gamma-radiation-resistant cell lines. J Nucl Med 2007, 48:1000-1007.
22. Kassis A.I., Sastry K.S., Adelstein S.J. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987, 109:78-89.
23. Kassis A.I., Adelstein S.J. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005, 46:4S-12S.
24. Sastry K.S. Biological effects of the Auger emitter iodine-125: a review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6. J Nucl Med 1992, 19:1361-1370.
25. Rahim S.G., Trivedi N., Bogunovic-Batchelor M.V., Hardy G.W., Mills G., Selway J.W., et al. Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. J Med Chem 1996, 39:789-795.
26. Yaccoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 2005, 11:7599-7606.
27. Schwarze M.M., Hawley R.G. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995, 55:2262-2265.
28. Urashima T., Nagasawa H., Wang K., Adelstein S.J., Little J.B., Kassis A.I. Induction of apoptosis in human tumor cells after exposure to Auger electrons: comparison with gamma-ray exposure. Nucl Med Biol 2006, 33:1055-1063.
29. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757.
30. Perillo-Adamer F., Kosinski M., Dupertuis Y.M., Viertl D., Bischof Delaloye A., Buchegger F. Fluorodeoxyuridine mediated cell cycle synchronization in S-phase increases the Auger radiation cell killing with 125I-iododeoxyuridine. Nuklearmedizin 2009, 48:233-242.
31. Akiyama M., Hideshima T., Hayashi T., Tai Y.T., Mitsiades C.S., Mitsiades N., et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002, 62:3876-3882.
32. Klein B., Zhang X.G., Lu Z.Y., Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995, 85:863-872.
33. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000.
34. Ram R., Uziel O., Eldan O., Fenig E., Beery E., Lichtenberg S., et al. Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 2009, 15:914-923.
35. Matsui W., Wang Q., Barber J.P., Brennan S., Smith B.D., Borrello I., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008, 68:190-197.
36. Kishikawa H., Wang K., Adelstein S.J., Kassis A.I. Inhibitory and stimulatory bystander effects are differentially induced by iodine-125 and iodine-123. Radiat Res 2006, 165:688-694.
37. O'Donoghue J.A., Wheldon T.E. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996, 41:1973-1992.
38. Desplanques G., Giuliani N., Delsignore R., Rizzoli V., Bataille R., Barillé-Nion S. Impact of XIAP protein levels on the survival of myeloma cells. Haematologica 2009, 94:87-93.
39. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-410.
40. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002, 99:14374-14379.